UK Markets close in 3 hrs 45 mins

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.2600+0.0400 (+0.95%)
At close: 04:00PM EST
4.2600 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.2200
Bid4.1800 x 1300
Ask0.0000 x 3000
Day's range4.2500 - 4.4180
52-week range4.2000 - 11.7400
Avg. volume1,888,841
Market cap510.335M
Beta (5Y monthly)2.50
PE ratio (TTM)N/A
EPS (TTM)-0.4980
Earnings date13 Apr 2022 - 18 Apr 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.33
  • Globe Newswire

    Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update

    Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose level, and (ii) treatment of patients with more than two cycles in the investigator sponsored trial of cord blood-derived natural killer (cbNK) cells pre-complexed with AFM13 (AFM13-104)Broad development strategy launched for AFM24 – enrollment initiated in three studies addressing major EGFR-expres

  • Globe Newswire

    Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference

    HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time. A live webcast of the presentation may be accessed on Affimed’s website at ht

  • Globe Newswire

    Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition

    AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus monkeysPre-complexing AFM13 with NK cells generates CAR-like NK cells, which retain biological activity and specificity after one cycle of freezing and thawing. This is an important prerequisite for the development of off-the-shelf products HEIDELBERG, Germany, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFM